Clinical trials: Blood Pressure Management
- Condition Blood Pressure Management
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hypertension
SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
To evaluate the effectiveness of diet management with a losartan based titration regimen versus losartan based titration regimen alone on blood pressure reduction in hypertensive patients.
- Trial name
- NCT00739674
- Testing
- losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]), Low Salt Diet
- Volunteers
- 992 people
- Sponsor
- Organon and Co
Primary Aldosteronism, Hyperaldosteronism
A Study of CIN-107 in Adults With Primary Aldosteronism
This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part…
- Trial name
- NCT04605549
- Testing
- CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Hypertension
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.
- Trial name
- VIPER-BP (NCT00902304)
- Testing
- Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care
- Where
- 3 sites in United States, Australia
- Volunteers
- 2,337 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients
The in-MAU-tion study is conducted to determine the percentage of hypertensive participants with or without diabetes reaching CHEP (Canadian Hypertension Education Program) defined blood pressure targets.
- Trial name
- in-MAU-tion (NCT01078584)
- Where
- 568 sites in Canada
- Volunteers
- 7,993 people
- Sponsor
- Abbott
Pediatric Perioperative Blood Pressure Management
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
Evaluate the efficacy, safety, and dosing of clevidipine as an intravenous (IV) infusion for blood pressure (BP) management in paediatric participants in the perioperative setting.
- Trial name
- PIONEER (NCT01938547)
- Testing
- clevidipine
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Hypertension
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E).
- Trial name
- NCT01302691
- Testing
- losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E), Losartan potassium, Amlodipine besylate
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Moderate to High-risk Noncardiac Surgery
Hypotension Prediction Index (HPI) SMART-BP Trial
A multicenter, randomized comparison of intraoperative hemodynamic management with or without a protocolized strategy utilizing Hypotension Prediction Index (HPI) software guidance during moderate-to-high-risk noncardiac surgery.
- Trial name
- NCT05105477
- Testing
- AcumenTM HPI Software Feature, Non-protocolized Standard of Care
- Where
- 11 sites in United States
- Volunteers
- 407 people
- Sponsor
- Edwards Lifesciences
Hypertension
Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine
To assess the pharmacodynamic effects of co-administrated SK3530 (PDE5 inhibitor) and Amlodipine, phase I study in Hypertensive patient was designed.
- Trial name
- NCT00626743
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- SK Chemicals Co., Ltd.
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.